AGE-RAGE in Multiple Sclerosis Brain

被引：31

作者：

Sternberg, Zohara ^{[1
]}

Ostrow, Peter ^{[1
]}

Vaughan, Mary ^{[2
]}

Chichelli, Trevor ^{[1
]}

Munschauer, Frederick ^{[1
]}

机构：

[1] Jacobs Neurol Inst, Dept Neurol, Buffalo, NY 14223 USA

[2] Roswell Pk Canc Inst, Dept Pathol, Buffalo, NY 14263 USA

来源：

IMMUNOLOGICAL INVESTIGATIONS | 2011年 / 40卷 / 02期

关键词：

Advanced glycation end-products; Alzheimer's disease; Immunohistochemistry; Multiple sclerosis; RAGE; GLYCATION END-PRODUCTS; ALZHEIMERS-DISEASE; MAILLARD REACTION; SOLUBLE RECEPTOR; RENAL-DISEASE; EXPRESSION; ATHEROSCLEROSIS; PROTEINS; GLYCOSYLATION; PATHOLOGY;

D O I：

10.3109/08820139.2010.532267

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

This pilot study used immunohistochemical techniques to investigate the advanced glycation end-product (AGE) Nepsilon-(carboxymethyl)lysine (CML) and its receptor (RAGE) in the brains of multiple sclerosis (MS) patients, comparing them with the brains of patients with Alzheimer's disease (AD) (positive controls) and with age-matched control subjects (negative controls). Postmortem slides derived from the hippocampi of MS patients, AD patients, and controls were stained with monoclonal antibodies for CML and human RAGE. Results showed increased AGE and RAGE immunostaining in the hippocampi of MS patients, similar to AD patients.</.

引用

页码：197 / 205

页数：9

共 31 条

[1] Relapsing and remitting multiple sclerosis: Pathology of the newly forming lesion [J].

Barnett, MH ;

Prineas, JW .

ANNALS OF NEUROLOGY, 2004, 55 (04) :458-468

[2] ADVANCED PROTEIN GLYCOSYLATION IN DIABETES AND AGING [J].

BROWNLEE, M .

ANNUAL REVIEW OF MEDICINE, 1995, 46 :223-234

[3]

Brownlee Michael., 1996, Current Opinion in Endocrinology, Diabetes and Obesity, V3, P291, DOI [DOI 10.1097/00060793-199608000-00003, 10.1097/00060793-199608000-00003]

[4] Lipid and lipoprotein modification by advanced glycosylation end-products: Role in atherosclerosis [J].

Bucala, R .

EXPERIMENTAL PHYSIOLOGY, 1997, 82 (02) :327-337

[5] Active glycation in neurofibrillary pathology of Alzheimer disease:: Nε-(carboxymethyl) lysine and hexitol-lysine [J].

Castellani, RJ ;

Harris, PLR ;

Sayre, LM ;

Fujii, J ;

Taniguchi, N ;

Vitek, MP ;

Founds, H ;

Atwood, CS ;

Perry, G ;

Smith, MA .

FREE RADICAL BIOLOGY AND MEDICINE, 2001, 31 (02) :175-180

[6]

Clynes R, 2007, CURR MOL MED, V7, P743

[7] Microglial activation and its implications in the brain diseases [J].

Dheen, S. Thameem ;

Kaur, Charanjit ;

Ling, Eng-Ang .

CURRENT MEDICINAL CHEMISTRY, 2007, 14 (11) :1189-1197

[8] Evaluation of rage isoforms, ligands, and signaling in the brain [J].

Ding, QX ;

Keller, JN .

BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH, 2005, 1746 (01) :18-27

[9] Identification of the advanced glycation end products Nε-carboxymethyllysine in the synovial tissue of patients with rheumatoid arthritis [J].

Drinda, S ;

Franke, S ;

Canet, CC ;

Petrow, P ;

Bräuer, R ;

Hüttich, C ;

Stein, G ;

Hein, G .

ANNALS OF THE RHEUMATIC DISEASES, 2002, 61 (06) :488-492

[10] Circulating levels of soluble receptor for advanced glycation end products in Alzheimer disease and vascular dementia [J].

Emanuele, E ;

D'Angelo, A ;

Tomaino, C ;

Binetti, G ;

Ghidoni, R ;

Politi, P ;

Bernardi, L ;

Maletta, R ;

Bruni, AC ;

Geroldi, D .

ARCHIVES OF NEUROLOGY, 2005, 62 (11) :1734-1736

← 1 2 3 4 →